VR

Venkata Reddy Arumalla

Active Director Additional Director DIN 01080639
DIN 01080639 First appointment Mar 1995 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Past companies 8 historical roles
Total affiliations 10 Since Mar 1995
Shareholding value β€’β€’β€’β€’ Premium profile

About Venkata Reddy Arumalla

Data last updated:

Venkata Reddy Arumalla is an Additional Director at Amrak Pharma Private Limited (since 2022) and Designated Partner at Connecticut Biotech India Llp (since 2020). The companies operate in Pharma, Chemicals and Chemicals and Materials. Earlier, Venkata Reddy Arumalla was a Whole-Time Director at Auro Property Management Services Limited (2011–2017) and Managing Director at Lancer Life Sciences Private Limited (2008–2010) and 6 more.

DIN 01080639
Primary Designation Additional Director
Industry Pharma
First Appointment 20 Mar 1995
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Amrak Pharma Private Limited U24303TG2021PTC157867
Additional Director09 May 20222021Active
Designated Partner02 Dec 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Whole-Time Director10 May 20112006₹21.63 Cr (FY 2025)Active
Lancer Life Sciences Private Limited U85110TG2005PTC047502
Managing Director08 Apr 20082005Active
Symed Labs Limited U24231TG1998PLC029961
Director02 Feb 20001998₹792 Cr (FY 2025)Amalgamated
Director20 Mar 19951984Under Process Of Striking Off
Synergy Remedies Private Limited U24232TG2011PTC122663
Director10 Mar 20112011₹24.32 Cr (FY 2025)Active
Genx Pharma Private Limited U24239TG1996PTC025371
Director11 Mar 19991996₹8,328 (FY 2025)Active
Director08 Nov 20162016Strike Off
Sanhoc Labs Limited U24232TG2011PLC076052
Director18 Aug 20112011₹2,000 (FY 2024)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Venkata Reddy Arumalla

Directorship timeline

Open interactive timeline →
Amrak Pharma Private Limited
Connecticut Biotech India Llp
Auro Property Management Services Limited
Lancer Life Sciences Private Limited
Premium access

Shareholding and investment profile for Venkata Reddy Arumalla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkata Reddy Arumalla

Venkata Reddy Arumalla currently holds 2 directorships: Amrak Pharma Private Limited (Additional Director, since 09 May 2022); Connecticut Biotech India Llp (Designated Partner, since 02 Dec 2020).

Venkata Reddy Arumalla was first appointed on 20 Mar 1995 as Director at Svs Drugs And Pharmaceuticals Pvt Ltd. The most recent appointment on record is 09 May 2022 at Amrak Pharma Private Limited.

Venkata Reddy Arumalla held 8 earlier board appointments: Auro Property Management Services Limited (Whole-Time Director, 10 May 2011 to 01 Apr 2017); Lancer Life Sciences Private Limited (Managing Director, 08 Apr 2008 to 02 Nov 2010); Symed Labs Limited (Director, 02 Feb 2000 to 06 Sep 2007); Svs Drugs And Pharmaceuticals Pvt Ltd (Director, 20 Mar 1995 to 28 May 2019); Synergy Remedies Private Limited (Director, 10 Mar 2011 to 15 Sep 2017); and 3 more.

The current boards of Venkata Reddy Arumalla's companies include Atluri Sreevarun (Amrak Pharma Private Limited), Lavanya Atluri (Amrak Pharma Private Limited), Makkapati Prudeesh Chakravarthi (Amrak Pharma Private Limited), Makkapati Soujanya (Amrak Pharma Private Limited), Samba Siva Rao Peddi (Amrak Pharma Private Limited), Swathi Ramaraju (Amrak Pharma Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available